Pink Biopharma
Monoclonal Antibody Therapy for Blood and Bone Cancer
Health Tech & Life Sciences
Non Active, Jul 2021 ceased to operate
Company Overview
Snapshot
Founded in May 2018 by Rachel Eren, Yael Yoffe-Mizrahi, and Prof. Angel Porgador, Pink Biopharma operates with 1–10 employees. The company has raised $3 million across one funding round from one investor. In October 2018, Pink Biopharma secured seed funding from FutuRx.
Business overview
Pink Biopharma is a drug-discovery company focused on developing a therapeutic monoclonal antibody. This technology acts as a natural-killer immune checkpoint inhibitor, specifically targeting various cancers, including acute myeloid leukemia. The company operates within the Health Tech & Life Sciences sector, with a focus on pharmaceuticals, and is a portfolio company of the FutuRx biotech incubator.
Company Intelligence Q&A
- What is Pink Biopharma's primary focus?
- Pink Biopharma is a drug-discovery company developing a therapeutic monoclonal antibody designed as a natural-killer immune checkpoint inhibitor for various cancers, particularly acute myeloid leukemia.
- When was Pink Biopharma founded?
- Pink Biopharma was founded in May 2018.
- Who are the founders of Pink Biopharma?
- Pink Biopharma was founded by Rachel Eren, Yael Yoffe-Mizrahi, and Prof. Angel Porgador.
- What is the status of Pink Biopharma?
- Pink Biopharma is currently non-active and ceased to operate in July 2021.
- Which incubator is Pink Biopharma a part of?
- Pink Biopharma is a portfolio company of the FutuRx biotech incubator.